

**FOR IMMEDIATE RELEASE**

**Urologix Announces Private Ownership**  
*Company focused on business continuity, growth through transition*

Minneapolis, Minn. (Feb. 10, 2016) – Urologix, the market leader for in-office minimally invasive medical products for the treatment of Benign Prostatic Hyperplasia (BPH), announces new private ownership and is operating as Urologix LLC. [Ash Keswani](#), a medical device industry veteran of more than 20 years, has been named President of the Limited Liability Company.

Urologix, LLC, which boasts 25 years of established industry leadership, will retain operations in Plymouth, Minn. The company's two leading product and service lines, Cooled ThermoTherapy™ and Prostiva® RF Therapy, will continue to be broadly available and customers will experience no disruption in sales or service.

“This is an exciting new chapter for Urologix. The change in ownership and elimination of all prior debt gives us the opportunity to invest in and ultimately expand the company's portfolio,” said Keswani. “While we focus on the future and build a strong growth trajectory for Urologix, our mission and commitment to customers will remain the same—to provide proven, life-changing treatments.”

As previously reported, the publicly-traded entity, Urologix Inc., was renamed 21<sup>st</sup> North Inc., which has no operations and plans to dissolve. All Urologix Inc. assets have been acquired by Urologix LLC.

###

**About Urologix LLC**

Urologix LLC, the leader in less invasive, in-office BPH treatment and based in Plymouth, Minn., develops, manufactures, markets and distributes minimally invasive medical products for the treatment of obstruction and symptoms due to Benign Prostatic Hyperplasia (BPH). Urologix's Cooled ThermoTherapy™ produces targeted microwave energy combined with a unique cooling mechanism to protect healthy tissue and enhance patient comfort. The Prostiva® RF Therapy System delivers radio frequency energy directly into the prostate destroying prostate tissue, reducing constriction of the urethra, and thereby relieving BPH symptoms. Both of these therapies provide safe, effective and lasting relief of the symptoms and obstruction due to BPH.

For more information, visit [www.urologix.com](http://www.urologix.com).

Contact:

Ash Keswani (612) 770-4783

[akeswani@urologix.com](mailto:akeswani@urologix.com)